PT-141.
About PT-141
PT-141 is studied in research on cellular energy metabolism and longevity. Unlike PDE5 inhibitors, PT-141 acts centrally via the MC4 receptor in the hypothalamus and modulates dopaminergic signaling rather than acting directly on vascular smooth muscle.
Research Application
Studied in sexual-function research, particularly regarding its central-nervous rather than vascular mechanism. In its approved form (Vyleesi), it is indicated exclusively for women with HSDD — data in men come from separate research.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
Research on longevity and energy metabolism is primarily supported by preclinical data.
- Clayton AH, et al. Obstet Gynecol. 2019;134(5):899–908. PMID 31599840
- Diamond LE, et al. J Sex Med. 2006;3(4):628–638. PMID 16839319
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Question about PT-141?
We reply personally – via email or Telegram.